Historique du chiffre d'affaires, des bénéfices et des flux de trésorerie d'après les états financiers officiels.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Voir les graphiques interactifs et les états complets → Modèle de valorisation (DCF) →
| Compte de résultat | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiffre d'affaires total | €1.0B | €692M | €364M | €267M | €51M | €8M | €7M | €13M | €11M | €2M | €5M | €8M | €14M | €20M | €16M |
| Bénéfice brut | €950M | €589M | €319M | €222M | €39M | €4M | €7M | €13M | €11M | €2M | €5M | €8M | €14M | €20M | €16M |
| Marge brute % | 90.6% | 85.1% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Résultat opérationnel (EBIT) | €266M | (€131M) | (€279M) | (€456M) | (€562M) | (€452M) | (€331M) | (€227M) | (€155M) | (€112M) | (€73M) | (€42M) | (€12M) | €5M | €2M |
| Marge opérationnelle % | 25.4% | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | -1583.2% | -515.2% | -85.7% | 25.9% | 9.7% |
| Résultat net | €753M | (€219M) | (€378M) | (€481M) | (€583M) | (€384M) | (€419M) | (€218M) | (€130M) | (€124M) | (€69M) | (€33M) | (€10M) | €4M | €1M |
| Marge nette % | 71.8% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% | -405.5% | -69.1% | 20.0% | 8.0% |
| EBITDA | — | (€110M) | (€290M) | (€411M) | (€529M) | (€365M) | (€408M) | (€210M) | (€150M) | (€110M) | (€72M) | (€33M) | (€11M) | €6M | €2M |
| Bénéfice par action (EPS) | €11.20 | €-3.61 | €-6.53 | €-8.55 | €-10.40 | €-7.00 | €-8.28 | €-4.69 | €-3.17 | €-3.68 | €-2.58 | €-1.39 | €-0.57 | €0.38 | €0.12 |
| Actions en circulation (M) | — | 61M | 58M | 56M | 56M | 55M | 51M | 47M | 41M | 34M | 27M | 24M | 17M | 11M | 11M |
Source : rapports publics de la société (SEC). Vérifiez sur SEC EDGAR avant de vous fier à tout chiffre.
Bilans, flux de trésorerie, données trimestrielles et ratios complets dans le visualiseur interactif de ASND. /companies/us/ASND
Les informations de ce site sont fournies à des fins éducatives et informatives uniquement ; elles ne constituent pas un conseil en investissement. Aucun objectif de cours ni recommandation n'est publié.
About TickerBase · Data methodology & sources · Privacy · Terms